Multiple myeloma is a cancer that develops in bone marrow plasma cells, crowding out healthy blood cells and damaging the bones.
Marcus Flores, PharmD, BCPS, BCOP, discusses the vital role of pharmacists in multidisciplinary cancer care, exploring ...
Histopathological image of multiple myoloma. Smear preparation of bone marrow aspirate stained with May-Grünwald-Giemsa procedure. It doest not represent a histopathologic image but essentially helps ...
Scientists from Mass General Brigham and the Broad Institute of MIT and Harvard have used CRISPR screens to identify genetic modifications that influence T cell function and survival in cultures and ...
A new study maps out the timeline of DNA damage for multiple myeloma, the second most common blood cancer. The findings may lead to better ways to group patients by the state of their DNA and define ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...
TARRYTOWN, N.Y., July 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for ...
The objective response rate was 70%, with 45% of patients achieving a complete response or better. The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic ™ (linvoseltamab ...
Please provide your email address to receive an email when new articles are posted on . The treatment is approved for heavily pretreated patients. Researchers reported an objective response rate of 70 ...
The Spanish Society of Hematology and Hemotherapy (SEHH) held its ninth “HematoAvanza” Outreach Conference at the Pazo de San Lorenzo in Santiago, Spain. The event brought together hematologists, ...
Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without detectable cancer for years after facing certain death. By Gina Kolata A ...